Last reviewed · How we verify
NCT05886634
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
Phase 2 trial testing Etrumadenant in Dedifferentiated Liposarcoma in 16 participants. Participants enrolled and being followed up; not accepting new ones.
23 May 2027
Quick facts
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 23 May 2023 |
| Primary completion | 23 May 2027 |
| Estimated completion | 23 May 2027 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- Etrumadenant — full drug profile →
- Zimberelimab — full drug profile →
Conditions studied
- Dedifferentiated Liposarcoma — all drugs for Dedifferentiated Liposarcoma →
- Soft Tissue Sarcoma — all drugs for Soft Tissue Sarcoma →
- Sarcoma,Soft Tissue — all drugs for Sarcoma,Soft Tissue →
- Sarcoma — all drugs for Sarcoma →
Sponsor
Memorial Sloan Kettering Cancer Center — full company profile →
Who can join
18 and older, any sex, with Dedifferentiated Liposarcoma or Soft Tissue Sarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Participants will have a diagnosis of dedifferentiated liposarcoma (DDLS) that has spread beyond its original location (advanced). In addition, their DDLS either has come back after treatment (recurrent), has spread to different parts of your body (metastatic), or is unable to be removed surgically (unresectable). The purpose of this study is to find out whether the combination of etrumadenant and zimberelimab is an effective treatment for people with advanced DDLS.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic potential of adenosine receptor modulators in cancer treatment.
Maity P, Ganguly S, Deb PK. · · 2025 · cited 13× · PMID 40530308 · DOI 10.1039/d5ra02235e -
Metabolic Signaling in the Tumor Microenvironment.
Clay R, Li K, Jin L. · · 2025 · cited 8× · PMID 39796781 · DOI 10.3390/cancers17010155 -
Insights from Clinical Trials on A<sub>2A</sub> Adenosine Receptor Antagonists for Cancer Treatment.
Deb PK, Maity P, Sarkar B, Venugopala KN, et al · · 2025 · cited 5× · PMID 40534663 · DOI 10.1021/acsptsci.5c00057 -
Natural Killer Cell-Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications.
Luo N, Chen C, Zhou W, Hao J, et al · · 2025 · cited 2× · PMID 40959206 · DOI 10.1002/mco2.70387 -
Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunities.
Liu H, Wang X, Liu L, Yan B, et al · · 2024 · cited 2× · PMID 39723387 · DOI 10.3389/fonc.2024.1484027
Verify or expand the search:
- PubMed search for NCT05886634
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Etrumadenant
Trials testing the same drug.
- NCT05335941 — A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Pa · Phase 2 · active not recruiting
- NCT05277012 — A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants · Phase 1 · completed
- NCT05154136 — A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in H · Phase 1 · completed
- NCT04791839 — Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patient · Phase 2 · active not recruiting
- NCT04660812 — An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participa · Phase 1, PHASE2 · completed
Other recruiting trials for Dedifferentiated Liposarcoma
Currently open trials in the same condition.
- NCT06975293 — STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants · Phase 1, PHASE2 · recruiting
- NCT06843967 — A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma · Phase 1, PHASE2 · recruiting
- NCT06389799 — A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) · Phase 2 · recruiting
- NCT03307616 — Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferen · Phase 2 · active not recruiting
Other Memorial Sloan Kettering Cancer Center trials
Trials by the same sponsor.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
- NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
- NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
- NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05886634 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
- Last refreshed: 20 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05886634.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing